利托那韦产品是Ritonavir is an orally bioavailable HIV-1 and HIV-2 protease inhibitor (EC₅₀ values are 0.022-0.13 and 0.16 μM, respectively). Through CYP3A4 inhibition, low doses of ritonavir can reduce the metabolism of concomitantly administered protease inhibitors, enhancing their bioavailability and efficacy.